D
Nurix Therapeutics, Inc. NRIX
$15.60 -$0.13-0.83% NASDAQ
Recommendation
Dividend Power Score
Prev Close
$15.73
Volume
766,969
Avg Vol (90D)
1,592,255
Market Cap
$1.62B
Dividend & Yield
--
52-Week Range
$8.18 - $22.50
P/E (TTM)
--
EPS (TTM)
-$3.04
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
Assessing Nurix Therapeutics (NRIX) Valuation After Revenue Growth Wider Loss And New Shelf Registration
2/9/2026 - Simply Wall St
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss
2/5/2026 - Simply Wall St
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory
2/3/2026 - Insider Monkey
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts
2/2/2026 - Yahoo! Finance: News
Research Analysts Offer Predictions for NRIX Q1 Earnings
2/2/2026 - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Olema Pharmaceuticals (OLMA), Nurix Therapeutics (NRIX)
1/31/2026 - TipRanks Financial Blog
Insider Selling: Nurix Therapeutics (NASDAQ:NRIX) CFO Sells 3,661 Shares of Stock
1/31/2026 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) CFO Sells $60,772.60 in Stock
1/31/2026 - Ticker Report
Houte Hans Van Sells 3,661 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock
1/31/2026 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,895 Shares
1/31/2026 - MarketBeat
H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX)
1/30/2026 - Yahoo! Finance: News
Nurix Therapeutics (NASDAQ:NRIX) Issues Quarterly Earnings Results
1/30/2026 - Ticker Report
Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress
1/30/2026 - Simply Wall St
Nurix Therapeutics (NRIX, $17.56) Stochastic Oscillator left the oversold zone on January 29, 2026
1/30/2026 - Tickeron - Stocks
Piper Sandler Raises Price Target on Nurix Therapeutics (NRIX) to $35 NRIX Stock News
1/29/2026 - GuruFocus
Royal Bank Of Canada Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price
1/29/2026 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Earns "Buy" Rating from BTIG Research
1/29/2026 - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Receives "Buy" Rating from Needham & Company LLC
1/29/2026 - MarketBeat
Nurix Therapeutics price target raised to $35 from $33 at Stifel
1/29/2026 - TipRanks Financial Blog
Nurix Therapeutics price target raised by $2 at Stifel, here's why
1/29/2026 - The Fly
Wall Street Analysts Are Bullish on Top Healthcare Picks
1/29/2026 - TipRanks Financial Blog
Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX)
1/29/2026 - TipRanks Financial Blog
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo
1/29/2026 - TipRanks Financial Blog
Nurix Therapeutics price target lowered by $1 at Wells Fargo, here's why
1/29/2026 - The Fly
Nurix Therapeutics price target lowered by $1 at Wells Fargo, here's why
1/29/2026 - The Fly
Income Statement
Total Revenue (TTM)
$83.98M
EBITDA (TTM)
-$277.53M
EBIT (TTM)
-$285.67M
Net Income (TTM)
-$264.46M
Balance Sheet
Total Assets (Q)
$688.14M
Total Debt (Q)
$55.73M
Total Liabilities (Q)
$149.39M
Book Value Per Share (Q)
$5.29
Cash Flow
Cash from Operations (TTM)
-$249.47M
Cash from Investing (TTM)
$147.85M
Cash from Financing (TTM)
$238.64M
Net Change in Cash (TTM)
$137.03M
Filings
Filing Date
Wednesday, January 28, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of Apr 6 and 10 (est)
Price History
Loading...
Beta
1.08
7-Day Total Return
-5.74%
30-Day Total Return
-17.76%
60-Day Total Return
21.97%
90-Day Total Return
56.78%
Year to Date Total Return
-13.62%
1-Year Total Return
-11.21%
2-Year Total Return
78.90%
3-Year Total Return
41.69%
5-Year Total Return
-60.93%
52-week Low
Apr 10, 2025 - $8.18
52-week High
Dec 08, 2025 - $22.50
Valuation
Market Cap
$1.62B - Small Cap
Enterprise Value
$1.08B
Price/Sales (TTM)
17.81
Price/Book (Q)
2.97
Dividends and Shares
Shares Outstanding
95.09M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.nurixtx.com
Phone Number
415 660 5320
Address
1600 Sierra Point Parkway
Brisbane, CA 94005
Country
United States
Year Founded
2009
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of... more
NASDAQ 02/13/2026 4:00PM Eastern Quotes delayed